

**SPENCER DAYMAN MENINGITIS RESEARCH**

**TRUSTEES ANNUAL REPORT AND FINANCIAL STATEMENTS  
FOR THE PERIOD ENDING  
31 MARCH 2025**

**Charity Numbers 1202202 England and Wales  
SC052732 Scotland**

## **SPENCER DAYMAN MENINGITIS RESEARCH**

<b>INDEX</b>	<b>Page</b>
General Information	3
Trustees Report	4
Trustees Responsibilities	11
Independent Examiners Report	12
Statement of Financial Activities	13
Balance Sheet	14
Statement of Cash Flows	15
Notes to the Accounts	16

## **SPENCER DAYMAN MENINGITIS RESEARCH**

### **GENERAL INFORMATION**

**Charity Number:** 1202202 and SC052732

**Type of Charity:** Charitable Incorporated Organisation

**Principal & Registered office address**

Homeside  
Old Gloucester Road  
Alveston  
Bristol  
BS35 3LQ

**Trustees**

Louise Graham – Chair  
Stephen Gazard  
Stephen S Dayman Jnr  
Quentin Stott  
David Booker

**Principal Officer**

Dr Steve Dayman MBE (Founder)

**Scientific Medical Advisory Panel**

Professor Paul Langford BSc PhD CBiol FRSB  
Professor Ray Borrow PhD MRCPATH  
Dr Caroline Vipond  
Professor Saul Faust FRCPCH PhD OBE  
Professor Ian Fevers BSc, PhD Appointed October 2024

**Independent Examiner**

Mathew Dobbins FCA  
Dunkley's Chartered Accountants  
Woodlands Grange  
Woodlands Lane  
Bradley Stoke  
Bristol  
BS32 4JY

**Bank**

Lloyds Bank  
PO Box 1000  
Andover  
BX1 1L

## SPENCER DAYMAN MENINGITIS RESEARCH

### Trustees' annual report for the period ending 31 March 2025

The Trustees present their report together with the financial statements for the period ending 31 March 2025.

#### Introduction from the Chair

We are delighted to present to you the 2025 Report and Accounts for Spencer Dayman Meningitis Research, which showcases our charity's progress and achievements in our 2nd financial year 2024-2025. The continued dedication of our supporters, volunteers and trustees resulted in exceeding our financial targets again and we are proud to share this achievement with them, so many of whom are families who have been affected by meningitis and other associated diseases. The financial support of grant giving Trusts and Foundations, community organisations, companies and individuals was truly appreciated.

We also extend our gratitude to our Scientific Medical Advisory Panel for their general advice and guidance, giving their time to monitor our first preventative vaccine development research project entitled: **Group A Strep Aviator Study** which commenced in October 2023. In addition, they evaluated and approved our 2<sup>nd</sup> preventative research study entitled: **Gold bionanoconjugates for the rapid detection of bacteria causing sepsis and meningitis**. This is a 12-month study to provide evidence to develop a diagnostic kit to detect sepsis, meningitis and other associated diseases in five minutes. This study commenced in November 2024. Their invaluable support ensures this charity funds relevant, meaningful preventative research of the highest quality.

Despite our successful year, the heart-breaking reality remains that there are still many infections that cause meningitis and other associated diseases that are not vaccine preventable. Since the end of the Covid pandemic, we have seen a rise in the number of infectious diseases including meningitis and other associated infections.

This confirms the continuing importance of our vital work, to fund preventative research, improve diagnosis into meningitis, sepsis and other associated diseases, support families affected and raise awareness regarding the signs and symptoms.

**Louise Graham**

## **SPENCER DAYMAN MENINGITIS RESEARCH**

### **Trustees' annual report for period ending 31<sup>st</sup> March 2025**

#### **Objects**

Spencer Dayman Meningitis Research was registered with the Charity Commission for England and Wales on 6 March 2023, and with the Office of the Scottish Charity Regulator on 7 August 2023.

The objects of the charity are:

1. To advance the education of the public in general (and particularly amongst scientists) in the prevention and treatment of meningitis and other associated diseases by promoting and funding research for the public benefit in all aspects of that subject and to publish the useful results.
2. For the public benefit, to relieve the needs of those affected by meningitis and other associated diseases, and their families by means of:
  - a. the provision of peer-to-peer support and practical advice;
  - b. raising public awareness.

The Trustees confirm that they have had regard to public benefit guidance published by the Charity Commission in determining the activities undertaken by the charity.

The charity does not employ any staff and relies entirely on volunteers, including our Principal Officer, Dr Steve Dayman MBE who also provides the office, rates, heat and light at no charge to the charity.

#### **Achievements and Performance**

The charity was registered on 6th March 2023 to support preventative scientific research into meningitis and other associated diseases, provide peer support to families affected by these diseases and raise awareness regarding the importance of recognising the signs and symptoms of meningitis and other associated diseases.

The charity's website ([www.spencerdaymanmeningitisresearch.org](http://www.spencerdaymanmeningitisresearch.org)) highlights our important work including providing diseases facts. We are grateful for the support of the Starfish Trust who continue to sponsor the maintenance of the website. We are also active on social media platforms including Facebook, Instagram and LinkedIn.

#### **Supporting preventative research at the Spencer Dayman Meningitis Laboratories, Bristol Vaccine Centre, University of Bristol.**

Progress continues regarding the development of safe and effective vaccines which Spencer Dayman Meningitis Research wholeheartedly supports.

We take great pride in ensuring that the preventative research we fund is of the highest quality. To achieve this, we rely on the expertise of our eminent Scientific Medical Advisory Panel, renowned for their knowledge and experience in infectious diseases. Their vast understanding in their respective fields is invaluable to us and we are grateful to them for giving their time to support our work.

## **SPENCER DAYMAN MENINGITIS RESEARCH**

### **Trustees' annual report for period ending 31<sup>st</sup> March 2025**

#### **Research Project: Aviator Group A Strep Vaccine Study: October 2024 – October 2027**

Our first research project, **Aviator Group A Study**, commenced on 1st October 2023. Group A Streptococcus (GAS) or "Strep A" is a bacterium which can cause a range of diseases from mild infections affecting the throat and skin to severe infections including meningitis, pneumonia, rheumatic fever and sepsis. It is estimated that GAS causes over half a million deaths each year worldwide, many of whom are children.

The diseases caused by GAS have been increasing in recent years, despite the availability of antibiotics to treat these infections. GAS bacteria are usually transmitted through the throat, mouth and nose. A vaccine which could prevent GAS from infecting the throat, mouth and nose would greatly reduce the impact of GAS diseases. There is no vaccine available for GAS and it is unclear which parts of the bacteria (called antigens) to include in a vaccine.

Lead scientists for this research project are:

- Dr Anu Goenka - Clinical Lecturer & Honorary Consultant in Paediatric Immunology & Infectious diseases
- Dr Alice Halliday – Lecturer in Infectious Diseases
- Prof Darryl Hill – Professor in Infectious Diseases

The team have developed an innovative approach that uses a new technique called tonsil organoid model. Tonsils are part of the immune system which help us fight infection. The research involves growing cells from tonsils of patients which were removed during routine surgery. To do this the team will separate out the cells and then grow the cells in the laboratory alongside different parts of the GAS bacteria. They will then measure the immune response of the tonsil cells from different donors to help them make decisions on which parts of the GAS bacteria could be included in a successful vaccine. Due to new findings and after consultation with our Scientific Medical Advisory Panel, the researchers will apply to Spencer Dayman Meningitis Research in the spring of 2025 to extend the project for a further two years. Scientific merit permitting, the extension will run to October 2027.

The Expected outputs are:

1. Peer-reviewed paper(s) within 2 years
2. Project grant or fellowship award with industry partnership to utilise findings

During the year, Dr Goenka presented his findings at Imperial College London and the University of Cardiff, with acknowledgements to Spencer Dayman Meningitis Research.

#### **Research Project: Gold bionanoconjugates for the rapid detection of bacteria causing sepsis and meningitis: November 2024 – October 2025**

This 12 month project aims to provide the evidence to develop a diagnostic kit to diagnose meningitis, sepsis and other bacterial disease in five minutes.

## **SPENCER DAYMAN MENINGITIS RESEARCH**

### **Trustees' annual report for period ending 31<sup>st</sup> March 2025**

Early onset of meningitis and sepsis is very difficult to detect and delay in medical treatment can often be catastrophic. In order to inform the most important type of treatment, it is essential to identify if the infection is caused by bacteria or a virus and specifically which bacteria.

At present, Identification can be slow, inaccurate and often leading to death and disability. The introduction of a rapid diagnostic kit has the potential to be rolled out not only in hospital environments but also health centers and GP surgeries. It will also reduce the deaths from meningitis and sepsis, and lifelong disability.

Lead scientists for this project are:

- Prof Darryl Hill - Professor in Infectious Diseases
- Dr Sean Davis - Senior Lecturer

Both the research teams have world-renowned reputations and have hosted investigators from around the world. These visits enhance the global scientific knowledge of meningitis and other associated diseases.

#### **Raising Awareness and Peer-to-Peer Support**

The charity promotes awareness of the important signs and symptoms of meningitis and other associated diseases on its website together with other disease information. Many families who have experienced the trauma that meningitis and other associated disease cause share their stories on our news pages to help raise awareness.

Disease awareness is also promoted through social media platforms. News items were also distributed to the print media nationally. Symptom cards and leaflets are distributed by volunteers to various locations local to where they live. During the year founder Dr Steve Dayman visited 26 families who have experienced meningitis and other associated diseases to provide peer-to-peer support, and other families were supported by phone.

#### **Fundraising Activities**

The driving force behind our fundraising activities are families that have been affected by meningitis and other associated diseases. Supporter fundraising has included:

- Sam Virgo Memorial Walk and Family Fun/Rounders Day in Gloucestershire raising over £3,000
- Golf Days in Nottingham organised by Colin Wagner and his son, Burt, in memory of Dylan Stott raising £2,100
- Neville Green's Golf Day in Cheshunt in memory of his niece, Alexandra, raising £1,200
- In Londonderry friends of Darren and Emma Cowie raised £1,100 from a sponsored football match

## **SPENCER DAYMAN MENINGITITS RESEARCH**

### **Trustees' annual report for the period ending 31<sup>st</sup> March 2025**

- Family and Friends of Andrew and Elaine Zographou raised £2,450 in memory of their son George
- Donations in memory of Chris Jackson raised over £2,000
- Carys Brannan and her sister Lois donated £1,150 in memory of their mother Meg
- Lynne Dodgson donated £1,200 from her aborted trip to the Great Wall of China in memory of her son Michael.

Many of our supporters and trustees made personal donations, helped with collections throughout the country and taken on their own fundraising event.

Grants from charitable trusts and foundations was the charity's largest income stream. Our sincere thanks go to the following charitable organisations who supported the charity this year:

Florence Shute Millennium Trust, The Ardwick Trust, N Ducker Charitable Trust, Starfish Trust, The Dagleish Trust, Bacta Charitable Trust, de Laszlo Foundation, The Forrester Family Charitable Trust, The Thriplow Charitable Trust, The Charles and Elsie Sykes Trust, The Grace Trust, The Coreus Foundation, The Webb Family Charitable Trust, The Sylvia Aitken Charitable Trust, The Garfield Weston Foundation, HDH Wills Charitable Trust, Stone King Foundation, The William Howarth Charitable Trust, Yvonne Flux Charitable Trust, The Hilda Clarke Memorial Fund, The Ian Askew Charitable Trust, The Wilmcote Chariturst, Santa Barbara Hights Charitable Trust, R G Hills Trust, Novia Foundation, the Michael & Anna Wix Charitable Trust

### **Financial Position**

During the year the charity raised £120,009. Expenditure was £43,029. Our prudent management of funds donated by our supporters kept our fundraising expenditure to just under £0.03 for every £1 raised.

Our surplus was £76,980, with £72,501 in restricted funds, £22,894 in designated funds (the amount committed but not covered by restricted funds), and £84,752 in our unrestricted fund. Cash held on 31 March 2025 was £181,437.

Full details of both Income and Expenditure can be found in the notes accompanying the Accounts.

The trustees are satisfied the charity is a going concern and fit for purpose. In the Trustees view, the reserves should provide the charity with adequate financial stability and the means for it to meet its charitable objectives for the foreseeable future. With no paid staff or premises, the trustees aim to hold sufficient funds to meet its primary expenditure commitments which is its research funding.

### **Reserves**

The Trustees review the amount of reserves regularly. As at 31 March 2024, all the funds required for the remainder of the existing research commitment are held in restricted (£72,501) and designated (£22,894) funds, and unrestricted reserves are £84,752.



## **SPENCER DAYMAN MENINGITIS RESEARCH**

### **Trustees' annual report for the period ending 31 March 2025**

#### **Pay and Expenses**

Spencer Dayman Meningitis Research is a voluntary organisation with no paid staff. Although the trustees can claim travel expenses, none were claimed during the year. Similarly, the Scientific Medical Advisory Panel were not remunerated nor did they claim expenses.

#### **Plans for 2025-2026**

Spencer Dayman Meningitis Research will continue to build on the success of its first 2 years to provide financial support towards innovative preventative research into meningitis, sepsis and other associated diseases. After discussions with our Scientific Medical Advisory Panel, we have invited scientists with track records into the prevention of infectious diseases at the Spencer Dayman Meningitis Laboratories, Bristol Vaccine Centre, University of Bristol to apply for research grant aid in the first quarter of the financial year 2025-26 with the aim of commencing the funding of new preventative research projects during the latter part of 2025 and beyond.

We will also continue to raise awareness about these diseases and provide peer-to-peer support and practical advice to families affected.

There are no plans to employ paid staff and we will continue to rely on our volunteers and supporters to help us deliver our objectives.

#### **Structure, Governance and Management**

Spencer Dayman Meningitis Research was registered with the Charity Commission on 6th March 2023 and with the Scottish Regulator (OSCR) on 7th August 2023. The charity is controlled by its governing document: Constitution of a Charitable Incorporated Organisation (CIO). The strategic direction of the charity is determined by the Board of Trustees in consultation with the Principal Officer, Dr Steve Dayman.

The Trustees meet at least 4 times a year to ensure effective governance and delivery against plans and budgets. A system of delegation is in place and day to day responsibility for the operation of the charity rests with the Principal Officer. Working closely with the Board, the Principal Officer is responsible for ensuring that the work of the charity is carried out in line with the strategic direction determined by the Board of Trustees.

The charity trustees are mindful of suitably skilled persons to join the Board and, through their networks, they are watchful for potential candidates.

Spencer Dayman Meningitis Research is a voluntary charity with no paid staff.

**SPENCER DAYMAN MENINGITIS RESEARCH**

**Trustees' annual report  
for the period ending 31 March 2025**


**Risk Management**

The Trustees are aware of the requirement under the Statement of Recommended Practice 2019 to regularly assess operating strengths, weaknesses and risks. The trustees have given consideration to the major risks the charity may be exposed to and are satisfied that appropriate controls are have been established to manage those risks.

**Fundraising Standards**

Spencer Dayman Meningitis Research is registered with the Fundraising Regulator ID number: FR.ID-274668. To date the charity has received no complaints about its fundraising activities since it was registered in March 2023.

Signed on behalf of the charity's board of trustees on 11/07/25 by

A handwritten signature in black ink, consisting of a stylized 'L' and 'G' followed by a horizontal line.

**Louise Graham, Chair**

## **SPENCER DAYMAN MENINGITIS RESEARCH**

### **Statement of Trustee Responsibilities**

The trustees of Spencer Dayman Meningitis Research are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Charity Commission requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose, with reasonable accuracy, at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

This report was approved by the Board on .....11/07/25..... and signed on its behalf by



**Louise Graham, Chair**

## SPENCER DAYMAN MENINGITIS RESEARCH

### Independent Examiner's Report to the Trustees of Spencer Dayman Meningitis Research

I report to the charity trustees on my examination of the accounts of the Trust for the year ended 31 March 2025.

#### Responsibilities and basis of report

As the trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities and Trustee Investment (Scotland) Act 2005 (the '2005 Act'), the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011 ('the 2011 Act'). You are satisfied that your charity is not required by charity law to be audited and have chosen instead to have an independent examination.


I report in respect of my examination of the Trust's accounts as carried out under section 44 (1)(c) of the 2005 Act and section 145 of the 2011 Act. In carrying out my examination I have followed the requirements of Regulation 11 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

#### Independent examiner's statement

Since the Trust has prepared its accounts on an accruals basis and is also registered in Scotland your examiner must be a member of a body listed in Regulation 11(2) of the Charities Accounts (Scotland) Regulations 2006 (as amended). I can confirm that I am qualified to undertake the examination because I am a registered member of ICAEW which is one of the listed bodies. I have completed my examination. I confirm that no matters have come to my attention giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by section 44 (1) (a) of the 2005 Act and Regulation 4 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements Regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Matthew Dobbins FCA  
Dunkley's Chartered Accountants  
Woodlands Grange  
Woodlands Lane  
Bradley Stoke  
Bristol  
BS32 4JY

Date 23/07/2025

**SPENCER DAYMAN MENINGITIS RESEARCH  
STATEMENT OF FINANCIAL ACTIVITIES  
(INCLUDING INCOME AND EXPENDITURE ACCOUNT)  
FOR THE PERIOD ENDING 31 MARCH 2025**

	Notes	Unrestricted Funds 2025 £	Restricted Funds 2025 £	Total Funds 2025 £	Total Funds 2024 £
<b>Income</b>					
Donations	2	56,346	62,765	119,111	119,046
Interest		898	-	898	
Fundraising events		-	-	-	13,219
<b>Total income</b>		<b>57,244</b>	<b>62,765</b>	<b>120,009</b>	<b>132,265</b>
<b>Expenditure on:</b>					
Generating funds		3,718	-	3,718	8,934
Charitable activities	3, 4				
- Research		654	30,233	30,887	9,949
- Support		4,961	-	4,961	4,319
- Awareness/Education		3,463	-	3,463	5,896
<b>Total expenditure</b>		<b>12,796</b>	<b>30,233</b>	<b>43,029</b>	<b>29,098</b>
<b>Net income before transfers</b>		<b>44,448</b>	<b>32,532</b>	<b>76,980</b>	<b>103,167</b>
Transfers between funds		-	-	-	-
<b>Net movement of funds in year</b>	10	<b>44,448</b>	<b>32,532</b>	<b>76,980</b>	<b>103,167</b>
<b>Reconciliation of funds:</b>					
Total funds brought forward		63,198	39,969	103,167	-
<b>Total funds carried forward</b>	10	<b>107,646</b>	<b>72,501</b>	<b>180,147</b>	<b>103,167</b>

The Statement of Financial Activities includes all gains and losses recognised in the year.


All income and expenditure derive from continuing activities.

**SPENCER DAYMAN MENINGITIS RESEARCH  
BALANCE SHEET  
AS AT 31 MARCH 2025**

	Notes	Unrestricted Funds £	Restricted Funds £	2025 £	2024 £
<b>Current Assets</b>					
Cash at bank		108,936	72,501	181,437	104,067
		108,936	72,501	181,437	104,067
<b>Creditors</b>					
Amounts due within one year	8	(1,290)	-	(1,290)	(900)
<b>Net Current Assets</b>		107,646	72,501	180,147	103,167
<b>Total Net Assets</b>	9	107,646	72,501	180,147	103,167
<b>The Funds of the Charity</b>					
Unrestricted income funds		84,752		84,752	43,138
Designated funds		22,894		22,894	20,060
Restricted income funds	10		72,501	72,501	39,969
		107,646	72,501	180,147	103,167

These accounts have been prepared in accordance with the provisions applicable to charitable incorporated organisations.

These accounts were approved by the Board of Trustees on 11/7/2025 and are signed on behalf of the board by:



.....  
Louise Graham  
Chair

**SPENCER DAYMAN MENINGITIS RESEARCH  
STATEMENT OF CASH FLOWS  
FOR THE PERIOD ENDING 31 MARCH 2025**

	<b>2025</b>	<b>2024</b>
	£	£
<b>Cash flows from operating activities:</b>		
Net movement in funds for the reporting period (as per the statement of financial activities)	76,980	103,167
Adjustments for:		
Decrease in debtors	-	-
Increase/(decrease) in creditors	390	900
Net cash provided by (used in) operating activities	77,370	104,067
<b>Change in cash and cash equivalents in the reporting period</b>	77,370	104,067
<b>Cash and cash equivalents at the beginning of the reporting period</b>	104,067	-
<b>Cash and cash equivalents at the end of the reporting period</b>	181,437	104,067

**SPENCER DAYMAN MENINGITIS RESEARCH  
NOTES TO THE ACCOUNTS  
FOR THE PERIOD ENDING 31 MARCH 2025**

**1. Accounting Policies**

The following accounting policies have been used consistently in dealing with items which are considered material in relation to the charity's accounts.

**(a) Basis of Accounting**

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The charity is a public benefit entity. The financial statements have been prepared on a going-concern basis. The trustees consider that the charity holds sufficient reserves to achieve an orderly closure in the unlikely event of a loss of funding.

The financial statements are presented in sterling which is the functional currency of the charity and rounded to the nearest £.

**(b) Going Concern**

There continues to be a need for the charity. With no paid staff, the only major expenditure commitment is research grant funding, and there are sufficient funds at the year end, held in a designated fund, to fully fund the current research commitments. In addition, the charity holds £84,752 in unrestricted reserves. The trustees are satisfied that the charity is a going concern.

**(c) Fund Accounting**

Unrestricted funds are general funds that are available for use at the trustees' discretion in furtherance of the objectives of the charity.

Restricted funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.

**(d) Income**

Income from donations, grants and contracts is recognised where there is entitlement, probability of receipt and the amount can be measured with sufficient reliability.

Investment income, trading income and other income are recognised on a receivable basis.

**(e) Expenditure**

Expenditure is recognised on an accruals basis. Expenditure includes any Value Added Tax which is reported as part of the expenditure to which it relates.

- Expenditure on generating funds comprises costs associated with attracting income.
- Expenditure on charitable activities comprises those costs incurred by the charity in the delivery of its research, peer support and awareness raising. It includes both costs that can be allocated directly to each of these and those costs of an indirect nature necessary to support them.
- Support costs are allocated between the expenditure categories of the Statement of Financial Activities on a basis designed to reflect the use of the resource.



**SPENCER DAYMAN MENINGITIS RESEARCH**  
**NOTES TO THE ACCOUNTS**  
**FOR THE PERIOD ENDING 31 MARCH 2025**

**(f) Taxation**

The charity is exempt from tax on income and gains falling within section 505 of the Taxes Act 1988 or section 252 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects.

**(g) Cash at bank**

Cash at bank is in a current account and short term deposit accounts.

**(h) Creditors**

Creditors are recognised where the charity has an obligation that will result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably.

**(i) Debtors**

Debtors are recognised where there is an obligation that will result in the transfer of funds to the charity and the amount owing can be measured,

**2 Income from Donations**

	Unrestricted	Restricted	2025	2024
	£	£	£	£
Donations	33,535		33,535	39,880
Gift Aid	2,197		2,197	626
Trusts & Grants	9,250	62,765	72,015	47,126
Legacies	10,146		10,146	23,714
Gifts in Kind	1,218		1,218	7,700
	<u>56,346</u>	<u>62,765</u>	<u>119,111</u>	<u>119,046</u>

**3 Expenditure on charitable activities**

	Unrestricted	Restricted	2025	2024
	£	£	£	£
Volunteer Expenses incl Travel	3,988	-	3,988	3,672
Research Grants & Equipment	-	30,233	30,233	7,907
Comms (incl PR & printed materials)	1,480	-	1,480	2,074
Web/Digital	730	-	730	4,268
Postage & Stationery	862	-	862	389
Support Costs (Note 4a)	368	-	368	553
Governance (Note 4a)	1,650	-	1,650	1,300
	<u>9,078</u>	<u>30,233</u>	<u>39,310</u>	<u>20,164</u>

**SPENCER DAYMAN MENINGITIS RESEARCH  
NOTES TO THE ACCOUNTS  
FOR THE PERIOD ENDING 31 MARCH 2025**

**4a Analysis of Support & Governance Costs 2025**

<b>Support</b>	<b>Research</b>	<b>Support</b>	<b>Awareness</b>	<b>Total Charitable Activities</b>	<b>Fundraising</b>	<b>Total 2025</b>
	£	£	£	£	£	£
IT costs	-	29	117	146	61	207
Insurance	65	65	66	196	66	262
ICO	-	13	13	26	14	40
	<u>65</u>	<u>107</u>	<u>196</u>	<u>368</u>	<u>141</u>	<u>509</u>

<b>Governance</b>	<b>Research</b>	<b>Support</b>	<b>Awareness</b>	<b>Total Charitable Activities</b>	<b>Fundraising</b>	<b>Total 2025</b>
	£	£	£	£	£	£
Independent Examiner	340	340	340	1,020		1,020
Professional Advice	120	120	120	360		360
Tax Return	90	90	90	270		270
	<u>550</u>	<u>550</u>	<u>550</u>	<u>1,650</u>	<u>-</u>	<u>1,650</u>

**4b Analysis of Support & Governance Costs 2024**

<b>Support</b>	<b>Research</b>	<b>Support</b>	<b>Awareness</b>	<b>Total Charitable Activities</b>	<b>Fundraising</b>	<b>Total 2024</b>
	£	£	£	£	£	£
IT Set up costs	127	126	127	380	127	507
Insurance	58	58	57	173	57	230
	<u>185</u>	<u>184</u>	<u>184</u>	<u>553</u>	<u>184</u>	<u>737</u>

<b>Governance</b>	<b>Research</b>	<b>Support</b>	<b>Awareness</b>	<b>Total Charitable Activities</b>	<b>Fundraising</b>	<b>Total 2024</b>
	£	£	£	£	£	£
Professional Fees re set up	134	133	133	400	-	400
Independent Examiner	300	300	300	900	-	900
	<u>434</u>	<u>433</u>	<u>433</u>	<u>1,300</u>	<u>-</u>	<u>1,300</u>

**SPENCER DAYMAN MENINGITIS RESEARCH  
NOTES TO THE ACCOUNTS  
FOR THE PERIOD ENDING 31 MARCH 2025**

**5 Independent Examiner's Remuneration**

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
IE Fees	1,020	900

**6 Staff Costs**

There are no staff employed by the charity. No trustees have been paid any remuneration or received any benefits from an employment within the charity. (2024 - £0)

**7 Related Party Transactions**

Donations were made by 2 trustees:

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Quentin Stott	-	10,116
Stephen Gazard	-	677
	-	10,793

Expenses were paid to our Principal Officer, Dr Steve Dayman MBE:

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Travel & Subsistence	4,355	6,472
IT Costs	151	547
Fundraising	241	377
Support Costs	40	-
Postage & Stationery	1,406	519
Comms	63	-
	6,256	7,915

No trustees had expenses reimbursed. (2024 - £0)

**8 Creditors – Amounts Falling Due Within One Year**

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Accruals and other creditors	1,290	900
	1,290	900

**SPENCER DAYMAN MENINGITIS RESEARCH  
NOTES TO THE ACCOUNTS  
FOR THE PERIOD ENDING 31 MARCH 2025**

**9a Analysis of Net Assets between Funds**

**Current year 2025**

	Unrestricted £	Restricted £	2025 £
Cash	108,936	72,501	181,437
Creditors less than 1 year	(1,290)	-	(1,290)
	<u>107,646</u>	<u>72,501</u>	<u>180,147</u>

**9b Analysis of Net Assets between Funds**

**Previous year 2024**

	Unrestricted £	Restricted £	2024 £
Cash	64,098	39,969	104,067
Creditors less than 1 year	(900)	-	(900)
	<u>63,198</u>	<u>39,969</u>	<u>103,167</u>

**10 Movements on Funds**

Current Year	Balance 31 Mar 2024 £	Income £	Expenditure £	Transfers £	Balance 31 Mar 2025 £
<b>Restricted Funds</b>					
Research	39,969	62,765	(30,233)	-	72,501
<b>Total Restricted Funds</b>	<u>39,969</u>	<u>62,765</u>	<u>(30,233)</u>	<u>-</u>	<u>72,501</u>
Designated Funds	20,060	-		2,834	22,894
Unrestricted Funds	43,138	57,244	(12,796)	(2,834)	84,752
<b>Total Funds</b>	<u>103,167</u>	<u>120,009</u>	<u>(43,029)</u>	<u>-</u>	<u>180,147</u>

Research Fund: Funds received towards current scientific research project being undertaken at Spencer Dayman Laboratories at Bristol University.

Designated Fund: Funds required for the completion of the current research project commitment.